Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN 20 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN 20 versus LIQREV.
LIPOSYN 20% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn 20% is an intravenous fat emulsion providing essential fatty acids (linoleic and linolenic acids) and triglycerides. It serves as a caloric source and prevents essential fatty acid deficiency by supplying substrate for energy metabolism and cell membrane synthesis.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Intravenous infusion: 1-2 g/kg/day (as soybean oil) initially, up to 2.5 g/kg/day, not to exceed 50% of total caloric intake; infusion rate not to exceed 0.1 g/kg/hour for first 30 minutes; if no adverse reactions, may increase to 0.2 g/kg/hour.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
Triglyceride clearance half-life approximately 30-60 minutes; depends on lipase activity and clinical status.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Lipids are metabolized; <10% excreted renally as free fatty acids; biliary/fecal excretion minimal.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion